ArticleAnnals of hematology2025
Daratumumab plus bortezomib and dexamethasone as a bridge to allogeneic transplantation in refractory T-cell lymphoblastic lymphoma.
Article in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Targeting CD38 in relapsed /refractory T-cell acute lymphoblastic leukemia/lymphoma: A systematic review of daratumumab-based therapy.Therapeutic advances in hematology · 2026Review
- Daratumumab-based salvage therapy enables umbilical cord blood transplantation in multiline refractory, elderly T-lymphoblastic lymphoma: a case report.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Relapsed and refractory (r/r) T-cell lymphoblastic lymphoma (T-LBL) is a highly lethal disease, with no effective treatment options. Daratumumab, an anti-CD38 human IgG1κ monoclonal antibody has been used as single agent in CD38 positive r/r T-LBL. We administered a salvage treatment with daratumumab in combination with bortezomib and dexamethasone regimen followed by allogeneic stem cell transplantation from HLA-haploidentical related donor in a 50 years old patient affected by cortical CD38 positive T-LBL, refractory to 2 prior therapies including first-line cyclophosphamide, vincristine, doxorubicin hydrochloride and dexamethasone (hyper-CVAD) regimen plus autologous stem cell transplantation. After 29 months he is alive and in sustained complete remission, emphasizing the role of daratumumab in combination with bortezomib and dexamethasone as a salvage treatment option in CD38 positive r/r T-LBL patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.